The AGILE platform master protocol allows incorporation of a range of identified and
yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the
trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols
of this master protocol as appendices. Having one master protocol ensures different
candidates are evaluated in the same consistent manor and opening up new trials for new
candidates is more efficient. Inclusion of new candidates will be determined by the AGILE
Scientific Advisory Board based on pre-clinical data, evidence in the clinical setting and
GMP capabilities.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Liverpool
Collaborators:
Lancaster University Liverpool School of Tropical Medicine Liverpool University Hospitals NHS Foundation Trust University of Cambridge University of Southampton